BioSpace News Archive

High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2-expressing advanced solid tumors, two secondary endpoints of the trial.

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection.

Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2023, which reflect continued execution against our strategic priorities.

Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the second quarter ended June 30, 2023 on August 10, 2023.

Cellinfinity Bio, a privately held biotechnology company developing first/best-in-class cell therapy products against solid tumors and other diseases, today announced the publication of a novel CAR enhancement, the addition of CTLA-4 intracellular domain to improve anti-tumor CAR-T activity.

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s second quarter 2023 financial results on Thursday, August 03, 2023, after the close of the U.S. financial markets.

Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William “Trey” Martin, III has assumed the role of Chief Executive Officer (CEO) of Maravai LifeSciences effective July 27, 2023, consistent with the Company’s previously announced CEO succession plan.

Invivyd, Inc., a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced the appointment of Sara Cotter to its board of directors.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced the appointment of Pius Maliakal, M. Pharm., Ph.D., as Vice President of Clinical Operations.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Thursday, Aug. 3, 2023 at 4:30 p.m. ET.